Concerning daycare images show children with their mouths taped shut in yoga exercise
The toddlers at Heritage House in Wahroonga, on Sydney's north shore, were participating in a breathing exercise as part of a yoga session last year.
No injuries were reported from the exercise which was meant to be relaxing, but the Department launched an investigation into the matter after concerns were raised by a parent.
'While no children were harmed in this incident, it was an inappropriate activity that should not have taken place in an early learning centre,' a spokesperson from the NSW Early Childhood Education and Care Regulatory Authority told news.com.au.
'A thorough investigation was immediately conducted and a compliance action issued to the approved provider, which remains on their record.' 
An external visitor was not running the yoga session, and the centre provided evidence to the Department that the mouth taping exercise has since been discontinued. 
In a statement, Heritage House told the Sydney Morning Herald: 'It was a well-intentioned activity led by one of our educators, a yoga instructor.'
'We accept that the Department issued a warning and as a result we took steps to ensure that the activity was not repeated.'
Photos of the activity were shared on the centre's parents app alongside a caption where an educator described the activity as 'unique'.
'The children gathered for a unique lesson combining breathwork, gentle yoga, and the tape-mouth technique. Guided to focus on nasal breathing, they playfully mimicked animals in yoga poses, learning to breathe deeply and calmly through their noses, fostering early mindfulness,' they wrote, according to SMH.
A number of parents whose children attend the daycare threw their support behind the centre and its educators on Tuesday.
One parent told 7News: 'They've always been very careful about the kids, their growth, their education, everything.'
Another said: 'People are friendly, they seem engaged, kids are happy here.'
Mouth taping, specifically for adults prone to mouth breathing while sleeping, has become a recent trend on TikTok but concerns have been raised about the dangers of restricting airflow.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
2 hours ago
- SBS Australia
'Heartbreaking reality': The essential products one in eight Australians can't afford
Millions of Australians could be living in hygiene poverty, with many struggling to afford basic items such as soap, toothpaste and deodorant. About one in eight people recently skipped buying personal hygiene or cleaning products to afford other essentials, according to research conducted on behalf of charity Good360 Australia. "Our research has uncovered the heartbreaking reality that millions of Australians are struggling to afford everyday basics," managing director Alison Covington said. 'Devastating toll' Hygiene poverty occurs when people are unable to afford everyday essential products such as soap, shampoo, toothpaste, deodorant, household cleaning products and feminine hygiene products. "Hygiene poverty can cause feelings of low self-esteem, embarrassment and shame, and make it difficult for people to maintain their health," Covington said. "It takes a devastating toll on people's mental and physical wellbeing." People unable to afford basic needs often avoid social events or commitments such as work and school, Covington said. The survey, involving a nationally representative sample of 1000 people, also found that one in seven respondents struggled to afford cleaning products in the last six months, while one in eight experienced hygiene poverty for the first time. A further 19 per cent feared they would soon be unable to afford hygiene or cleaning products and 12 per cent of people were experiencing hygiene poverty for the first time. Women and young people were more likely to be impacted by the issue, with almost a third of young people and 21 per cent of women concerned about affording essential hygiene and cleaning products, compared to 16 per cent of men. Liverpool Women's Health Centre, in Sydney's southwest, helps more than 5000 women per year and has found personal items such as soap, deodorant and feminine hygiene products to be in high demand. "Everyday women that you wouldn't necessarily expect to need a deodorant or a packet of soap are taking it," chief executive Kate Meyer said. Meyer said one of the centre's elderly clients was "over the moon with gratitude" when she was given incontinence products. "That's horrifying for us because these are things that she needs for her everyday living," she said. "They shouldn't be something that gives her such joy. "They should be things that she's able to get in her groceries every week." Good360 channels unsold consumer goods to charities and disadvantaged schools to help people in need, preventing the surplus goods from going to landfill.
ABC News
2 hours ago
- ABC News
Canberra Parkinson's community still campaigning for specialist nurse
Canberra's Parkinson's community has long been campaigning for the ACT government to employ a specialist Parkinson's nurse who can visit patients at home.
News.com.au
2 hours ago
- News.com.au
ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July. The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index. Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July. "During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead. "Healthcare has been beaten down for quite a long while now and is starting to look attractive. "I don't think there was anything specific in terms of a catalyst to drive the rotation." Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals. "Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said. He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products. "Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said. "As a result, imported plasma products are critical to meeting national demand. "Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm." How ASX biotechs performed in July CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP PAB Patrys Limited $ 0.002 181.8% 6.9 LDX Lumos Diagnostics $ 0.073 170.4% 55.4 NSB Neuroscientific $ 0.235 170.1% 79.8 NXS Next Science Limited $ 0.140 109.0% 41.7 NOX Noxopharm Limited $ 0.110 103.7% 30.7 CMB Cambium Bio Limited $ 0.425 102.4% 8.2 DVL Dorsavi Ltd $ 0.028 86.7% 27.3 ICR Intelicare Holdings $ 0.013 85.7% 6.3 CC5 Clever Culture $ 0.029 81.3% 56.9 EMD Emyria Limited $ 0.049 75.0% 28.1 CU6 Clarity Pharma $ 4.370 74.8% 1,471.5 HMD Heramed Limited $ 0.012 71.4% 10.5 MX1 Micro-X Limited $ 0.083 69.4% 54.0 TTX Tetratherix Limited $ 5.020 66.2% 131.7 CAN Cann Group Ltd $ 0.016 60.0% 9.8 NYR Nyrada Inc. $ 0.370 54.2% 77.8 VBS Vectus Biosystems $ 0.06 50.0% 3.2 CSX Cleanspace Holdings $ 0.760 46.2% 59.5 MSB Mesoblast Limited $ 2.380 43.8% 3,046.3 AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9 HIQ Hitiq Limited $ 0.020 42.9% 9.9 AYA Artryalimited $ 1.025 42.4% 116.7 ANR Anatara Ls Ltd $ 0.007 40.0% 1.5 ATH Alterity Therap Ltd $ 0.014 40.0% 128.9 CBL Control Bionics $ 0.040 37.9% 12.1 EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2 IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0 IPD Impedimed Limited $ 0.047 34.3% 93.4 RCE Recce Pharmaceutical $ 0.388 33.6% 108.4 NTI Neurotech Intl $ 0.020 33.3% 21.0 VFX Visionflex Group Ltd $ 0.00 33.3% 6.7 AT1 Atomo Diagnostics $ 0.018 28.6% 14.2 AHC Austco Healthcare $ 0.370 27.6% 137.0 TRP Tissue Repair $ 0.240 26.3% 14.5 SOM SomnoMed Limited $ 0.815 25.4% 171.8 1AD Adalta Limited $ 0.003 25.0% 2.8 ADR Adherium Ltd $ 0.005 25.0% 9.0 BIT Biotron Limited $ 0.003 25.0% 3.3 CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5 FRE Firebrickpharma $ 0.077 24.2% 17.5 CMP Compumedics Limited $ 0.315 23.5% 66.3 NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6 ILA Island Pharma $ 0.170 21.4% 40.8 ATX Amplia Therapeutics $ 0.240 20.0% 111.9 DOC Doctor Care Anywhere $ 0.125 19.0% 47.7 EBR EBR Systems $ 1.410 18.0% 514.6 LTP Ltr Pharma Limited $ 0.340 17.2% 60.6 PAR Paradigm Bio. $ 0.355 16.4% 136.1 LGP Little Green Pharma $ 0.115 16.2% 35.1 M7T Mach7 Tech Limited $ 0.380 15.2% 89.3 ALC Alcidion Group Ltd $ 0.115 15.0% 154.4 NC6 Nanollose Limited $ 0.077 14.9% 24.1 CYC Cyclopharm Limited $ 1.040 14.3% 113.4 SPL Starpharma Holdings $ 0.100 13.6% 43.9 MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8 SNT Syntara Limited $ 0.060 13.2% 97.6 CSL CSL Limited $ 270.900 13.1% 128,514.7 PME Pro Medicus Limited $ 321.890 12.9% 33,058.3 CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2 IMM Immutep Ltd $ 0.270 12.5% 385.3 MVP Medical Developments $ 0.610 11.9% 64.8 TRJ Trajan Group Holding $ 0.800 11.9% 121.9 GLH Global Health Ltd $ 0.076 11.8% 4.5 VIT Vitura Health Ltd $ 0.07 11.3% 47.0 PIQ Proteomics Int Lab $ 0.360 10.8% 57.3 IRX Inhalerx Limited $ 0.042 10.5% 9.0 IDT IDT Australia Ltd $ 0.098 10.1% 40.7 NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2 PGC Paragon Care Limited $ 0.400 9.6% 653.8 RHY Rhythm Biosciences $ 0.059 9.3% 17.4 1AI Algorae Pharma $ 0.006 9.1% 10.1 CTQ Careteq Limited $ 0.012 9.1% 2.8 AHX Apiam Animal Health $ 0.565 8.7% 103.0 ARX Aroa Biosurgery $ 0.630 8.6% 224.3 OCC Orthocell Limited $ 1.275 8.5% 309.7 MAP Microbalifesciences $ 0.092 8.2% 47.4 PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9 PNV Polynovo Limited $ 1.290 7.9% 858.4 RMD ResMed Inc. $ 42.450 7.9% 61,930.3 PTX Prescient Ltd $ 0.047 6.8% 38.7 REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6 TYP Tryptamine Ltd $ 0.03 6.7% 44.6 SDI SDI Limited $ 0.883 6.3% 104.6 COH Cochlear Limited $ 318.520 6.0% 20,541.2 RHC Ramsay Health Care $ 38.770 5.7% 8,808.5 IDX Integral Diagnostics $ 2.670 5.1% 1,001.8 IMC Immuron Limited $ 0.064 4.9% 16.9 OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5 EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6 RAD Radiopharm $ 0.023 4.5% 54.4 ACW Actinogen Medical $ 0.024 4.3% 76.3 IIQ Inoviq Ltd $ 0.385 4.1% 43.5 AGH Althea Group $ 0.026 4.0% 21.4 IME Imexhs Limited $ 0.300 3.4% 15.8 CYP Cynata Therapeutics $ 0.155 3.3% 37.3 SHL Sonic Healthcare $ 27.610 3.1% 13,532.2 FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0 CTE Cryosite Limited $ 0.750 0.7% 36.6 VLS Vita Life Sciences.. $ 2.26 0.4% 124.4 ACR Acrux Limited $ 0.016 0.0% 7.0 BP8 Bph Global Ltd $ 0.002 0.0% 2.1 EMV Emvision Medical $ 1.740 0.0% 150.1 EOF Ecofibre Limited $ 0.020 0.0% 7.6 EPN Epsilon Healthcare $ 0.024 0.0% 7.2 NAN Nanosonics Limited $ 4.050 0.0% 1,196.3 OSX Osteopore Limited $ 0.011 0.0% 2.6 TD1 Tali Digital Limited $ 0.001 0.0% 4.2 TRI Trivarx Ltd $ 0.008 0.0% 5.0 TRU Truscreen $ 0.016 0.0% 12.3 ACL Au Clinical Labs $ 2.760 -0.7% 536.1 CGS Cogstate Ltd $ 1.730 -0.9% 292.9 MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4 ANN Ansell Limited $ 29.950 -1.1% 4,410.5 AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6 RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7 RAC Race Oncology Ltd $ 1.160 -1.3% 198.9 SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8 HLS Healius $ 0.770 -1.9% 548.2 ALA Arovella Therapeutic $ 0.098 -2.0% 117.7 BMT Beamtree Holdings $ 0.245 -2.0% 72.6 ONE Oneview Healthcare $ 0.245 -2.0% 185.7 4DX 4Dmedical Limited $ 0.235 -2.1% 136.2 COV Cleo Diagnostics $ 0.380 -2.6% 48.8 RHT Resonance Health $ 0.038 -2.6% 17.5 AVH Avita Medical $ 1.670 -2.6% 217.6 SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4 PYC PYC Therapeutics $ 1.240 -4.2% 729.1 IXC Invex Ther $ 0.085 -4.5% 6.9 OIL Optiscan Imaging $ 0.105 -4.5% 87.7 ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9 MDR Medadvisor Limited $ 0.075 -7.4% 43.8 BDX Bcaldiagnostics $ 0.058 -7.9% 20.5 GSS Genetic Signatures $ 0.330 -9.6% 76.1 CDX Cardiex Limited $ 0.036 -10.0% 18.7 PER Percheron $ 0.009 -10.0% 10.9 AGN Argenica $ 0.680 -10.5% 86.1 OSL Oncosil Medical $ 1.070 -10.8% 20.2 ECS ECS Botanics Holding $ 0.008 -11.1% 11.0 PEB Pacific Edge $ 0.085 -11.5% 75.9 IVX Invion Ltd $ 0.096 -12.7% 8.2 EZZ EZZ Life Science $ 2.030 -13.2% 99.1 TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3 AVR Anteris Technologies $ 5.130 -16.4% 179.8 DXB Dimerix Ltd $ 0.470 -18.3% 285.1 SHG Singular Health $ 0.300 -18.9% 93.5 IMR Imricor Med Sys $ 1.225 -19.4% 324.2 MEM Memphasys Ltd $ 0.004 -20.0% 7.9 PCK Painchek Ltd $ 0.035 -22.2% 66.3 CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4 VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4 UCM Uscom Limited $ 0.01 -31.3% 2.9 UBI Universal Biosensors $ 0.02 -31.4% 7.2 IMU Imugene Limited $ 0.270 -38.9% 77.2 BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3 Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets. In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m. Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market. The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company. Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation. The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network. The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination. Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program. Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company". 'I have never done a deal that fast,' Taylor said. 'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .' At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.
